Actively Recruiting
A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health
Led by Lesaffre International · Updated on 2026-03-25
240
Participants Needed
1
Research Sites
35 weeks
Total Duration
On this page
Sponsors
L
Lesaffre International
Lead Sponsor
P
People Science
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study evaluates the effect of two different doses of a consumer-grade product, MyCondro™, on individuals experiencing mobility issues related to knee osteoarthritis. The primary goal is to measure improvements in overall joint health and mobility by tracking changes in participants' total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores from the beginning to the end of the trial. Additionally, the study aims to assess secondary outcomes, including the product's impact on pain, stiffness, knee function, patient-reported improvement, inflammatory blood markers (CRP), and daily physical activity.
CONDITIONS
Official Title
A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals age 45 years and older
- BMI between 18 and 35 kg/m8
- Self-reported mobility issues and joint discomfort related to a known diagnosis of Knee Osteoarthritis for at least 6 months and active in the last 3 months
- Willingness to avoid foods high in Chondroitin Sulfate and supplements containing Chondroitin Sulfate during the study
- Able to read and understand English
- Able to provide informed consent
- Able to use a smartphone and download the Chloe app
- Able to receive shipments within the United States
- Able to complete study assessments for up to 16 weeks
You will not qualify if you...
- No personal smartphone, no internet access, or unwilling to download the Chloe app
- Use of Chondroitin Sulfate supplements within 3 months prior to randomization
- Use of other joint health supplements for at least 4 weeks prior to randomization
- Use of intra-articular or intravenous steroid injections in the last 3 months
- Use of investigational therapies within 30 days prior to randomization
- Self-reported inflammatory arthropathies (e.g., Rheumatoid Arthritis, Gout, Infectious Arthritis)
- Significant lung, liver, heart, or kidney disease (excluding hypertension)
- Knee surgery within 3 months before or planned during the study
- Current diagnosis of Alcohol or Substance Use Disorder
- Currently pregnant, planning pregnancy in next 20 weeks, or breastfeeding
- Presence of a knee prosthesis
- Known allergy or sensitivity to Chondroitin sulfate or study ingredients
- Known sensitivity or intolerance to wheat or gluten
- Unlikely to comply with trial or deemed unsuited by the Principal Investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
People Science
Los Angeles, California, United States, 90045
Actively Recruiting
Research Team
V
Victoria Oyedokun, PhD
CONTACT
Y
Yann Fardini, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here